Ioxilan

Chemical compound
  • V08AB12 (WHO)
Legal statusLegal status
  • US: ℞-only
  • Discontinued
Pharmacokinetic dataBioavailabilityN/AProtein bindingnegligibleMetabolismnoneElimination half-life2 hoursExcretionMostly renalIdentifiers
  • 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
  • 107793-72-6 ☒N
PubChem CID
  • 3743
DrugBank
  • DB09135 checkY
ChemSpider
  • 3612 checkY
UNII
  • A4YJ7J11TG
KEGG
  • D02161 checkY
ChEMBL
  • ChEMBL1201075 ☒N
CompTox Dashboard (EPA)
  • DTXSID0048717 Edit this at Wikidata
Chemical and physical dataFormulaC18H24I3N3O8Molar mass791.116 g·mol−13D model (JSmol)
  • Interactive image
  • O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
  • InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) checkY
  • Key:UUMLTINZBQPNGF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]

Mechanism of action

Ioxilan is an iodinated contrast agent.[2]

References

  1. ^ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641969.
  2. ^ a b Oxilan FDA Professional Drug Information. Accessed 2021-04-07.
  • v
  • t
  • e
X-ray and CT
Iodinated,
Water soluble
Nephrotropic,
high osmolar
Nephrotropic,
low osmolar
Hepatotropic
Iodinated,
Water insoluble
Non-iodinated
MRI
Paramagnetic
Superparamagnetic
Other
Ultrasound
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e